NovoCure (FRA:038) Cyclically Adjusted PB Ratio: (As of Sep. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:038 NovoCure Ltd FRA:038
73 GF Score
Price €14.37
GF Value €16.89
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is NovoCure Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


NovoCure  (FRA:038) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


NovoCure Cyclically Adjusted PB Ratio Related Terms


NovoCure Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for NovoCure's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NovoCure Cyclically Adjusted PB Ratio Chart

NovoCure Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 15.34 4.13 9.64 3.72

NovoCure Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.09 3.68 3.81 3.03 4.74

FRA:038 vs ESTA, ALMR, BFLY: Cyclically Adjusted PB Ratio Comparison

For the Medical Devices subindustry, NovoCure's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NovoCure Cyclically Adjusted PB Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NovoCure's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where NovoCure's Cyclically Adjusted PB Ratio falls into.


FRA:038
73GF Score
NovoCure Ltd FRA:038
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NovoCure Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

NovoCure's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, NovoCure's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=2.54/333.9520*333.9520
=2.540

Current CPI (Jun. 2026) = 333.9520.

NovoCure Quarterly Data

Book Value per Share CPI Adj_Book
201609 1.642 241.428 2.271
201612 1.550 241.432 2.144
201703 1.367 243.801 1.872
201706 1.163 244.955 1.586
201709 1.105 246.819 1.495
201712 1.057 246.524 1.432
201803 0.954 249.554 1.277
201806 1.038 251.989 1.376
201809 1.064 252.439 1.408
201812 1.053 251.233 1.400
201903 1.176 254.202 1.545
201906 1.426 256.143 1.859
201909 1.765 256.759 2.296
201912 1.949 256.974 2.533
202003 2.197 258.115 2.843
202006 2.360 257.797 3.057
202009 2.574 260.280 3.303
202012 3.806 260.474 4.880
202103 3.068 264.877 3.868
202106 3.232 271.696 3.973
202109 3.434 274.310 4.181
202112 3.472 278.802 4.159
202203 3.747 287.504 4.352
202206 4.034 296.311 4.546
202209 4.332 296.808 4.874
202212 3.935 296.797 4.428
202303 3.746 301.836 4.145
202306 3.574 305.109 3.912
202309 3.483 307.789 3.779
202312 3.065 306.746 3.337
202403 3.092 312.332 3.306
202406 3.125 314.175 3.322
202409 2.990 315.301 3.167
202412 3.205 315.605 3.391
202503 3.006 319.799 3.139
202506 2.663 322.561 2.757
202509 2.594 324.800 2.667
202512 2.577 324.054 2.656
202603 2.478 330.213 2.506
202606 2.540 333.952 2.540

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is NovoCure (FRA:038) Overvalued in 2026?

Based on GuruFocus' analysis, NovoCure stock appears to be undervalued. The current stock price of €14.37 is trading 14.9% below its estimated GF Value™ of €16.89. GuruFocus considers NovoCure to be Modestly Undervalued.

Key valuation signals for FRA:038:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: €16.89 vs. price of €14.37 (14.9% below fair value)
  • GF Score™: 73/100 with 3 warning signs

No single metric tells the full story. See the FRA:038 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


NovoCure Business Description

Address Grenville Street, No. 4 The Forum, Second Floor, St. Helier, JEY, JE2 4UF
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
73GF Score

Get the complete analysis for FRA:038

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€14.37
Price
€16.89
GF Value